---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-116942"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:03:52.121183+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Elanco appoints Stacey Ma to board; board expands to 15 members

## Summary
- Ma appointed effective Nov 11, 2024; board increased from 14 to 15 directors.
- Ma will serve on Innovation, Science and Technology Committee.
- Ma is EVP of Pharmaceutical Development and Manufacturing at Gilead Sciences.
- Her expertise in CMC and drug development supports Elanco's IPP strategy.
- No related party transactions or arrangements in her appointment.

## SEC filing metadata
- accession: 0001104659-24-116942
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000110465924116942/0001104659-24-116942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000110465924116942/tm2428235d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-116942
- JSON: https://secwatch.observer/filing/0001104659-24-116942.json
- Plain text: https://secwatch.observer/filing/0001104659-24-116942.txt

## Key facts
- Executive change
  Stacey Ma was appointed as Director at Elanco Animal Health Inc.
  - Action: appointed
  - Role: Director
  source text: On November 11, 2024, the Board of Directors (the “Board”) of Elanco Animal Health Incorporated (the “Company”) appointed Stacey Ma, PhD, to the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739104/000110465924116942/0001104659-24-116942-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.